March 27, 2024 – Lyrica (Pregabalin) is a drug from the group of gabapentinoids and is an anticonvulsant active ingredient. It has been approved throughout the EU since 2004 for the treatment of neuropathic pain, epilepsy and generalized anxiety disorder. …

Lyrica (Pregabalin): Thousands of deaths? Read more »

August 22, 2021 – A new study of the genetics underlying facial features finds that East Africans have some unique facial genetics and some that are shared with Europeans. The findings, published August 19th in PLOS Genetics by Chenxing Liu, …

Study of East Africans illuminates new genetic factors underlying human faces Read more »

April 03, 2020 – Medulloblastoma is the most common malignant pediatric brain tumor. Medulloblastomas are invasive, rapidly growing tumors that, unlike most brain tumors, spread through the cerebrospinal fluid and frequently metastasize to different locations along the surface of the …

Inherited mutation in ELP1 predisposes children to medulloblastoma Read more »

January 31, 2018 – Chocolate and the sweet taste receptor gene TAS1R2 may make the life of some obese children and adolescents rather difficult in that genetic variations in TAS1R2 appear related to chocolate powder and dietary fiber intake in these …

Chocolate and the sweet taste receptor gene TAS1R2 Read more »

January 19, 2018 – Patients suffering from amyotrophic lateral sclerosis (ALS) find value in genetic testing for the disease, whether or not they have a family history of the condition, according to findings from a survey conducted by U.S. researchers, …

Is genetic testing of value for ALS patients? Read more »

November 18, 2016 –  Do we really need another steroid hormone to treat women? If yes, does it have to be DHEA? The American Food & Drug Administration (FDA) thinks so.  FDA just approved  Prasterone (Intrarosa) to treat women experiencing …

Intrarosa Postmenopausal Read more »

February 07, 2016 – The European Commission has approved once-daily Osimertinib (Tagrissa) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that is positive for the epidermal growth-factor receptor (EGFR) T790M mutation. This follows a positive review in …

Osimertinib (Tagrissa) approved for non-smal cell lung cancer (NSCLC) patient subgroup carrying the EGFR T790M mutation Read more »